HSHisato Shima

Hisato Shima

*This is an algorithmically generated author record based on publicly available information.

Hisato Shima has a total of 132 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tenapanor‒induced drug eruption in hemodialysis patient: A case report

    by Hisato Shima, Hiroyoshi Nakatsuji, Manabu Sakaki, Yoshihide Murakami, Takumi Hamao

    82歳男性.高リン血症に対して,選択的Na/H交換輸送体3阻害であるテナパノルの内服を開始した.内服開始28日後に,体幹,両上腕,両大腿に掻痒を伴う,びまん性紅斑を認め,入院した.テナパノルによる薬疹が疑われたため,テナパノルを中止し,第7病日には皮疹の改善を認めた.第9病日にテナパノルの薬剤誘発性リンパ球刺激試験を施行したが,陰性であった.テナパノル中止のみで薬疹が速やかに改善したこと,テナパノル以外の内服薬をすべて継続しても,症状の再燃がないことから,テナパノルが原因薬剤である可能性が高いと考えられた.テナパノルは消化器系の副作用報告が多いが,本症例のように薬疹の原因薬剤となり得ることも念頭に置く必要がある.

  • Open Access

    The Far Negative Intercept of the Regression Formula Obtained from Repeated Measurements of BChE and Albumin Levels is Useful for Detecting Hereditary Heterozygous Butyrylcholinesterase Deficiency in Patients on Dialysis

    by Naoki Tokunaga, Hisato Shima, Takuya Okamoto, Masato Maekawa, Jun Minakuchi

    Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.

  • The association between renal medullary and cortical fibrosis, stiffness, and concentrating capacity: an observational, single-center cross-sectional study

    by Hisato Shima, Toshio Doi, Yukari Yoshikawa, Takuya Okamoto, Manabu Tashiro, Tomoko Inoue, Kazuyoshi Okada, Jun Minakuchi

    Background Fibrosis is a common final pathway leading to end-stage renal failure. As the renal medulla and cortex contain different nephron segments, we analyzed the factors associated with the progression of renal medullary and cortical fibrosis. Methods A total of 120 patients who underwent renal biopsy at Kawashima Hospital between May 2019 and October 2022 were enrolled in this retrospective study. Renal medullary and cortical fibrosis and stiffness were evaluated using Masson’s trichrome staining and shear wave elastography, respectively. Maximum urine osmolality in the Fishberg concentration test was also examined. Results Medullary fibrosis was positively correlated with cortical fibrosis (p < 0.0001) and log-converted urinary β2-microglobulin (MG) (log urinary β2-MG) (p = 0.022) and negatively correlated with estimated glomerular filtration rate (eGFR) (p = 0.0002). Cortical fibrosis also correlated with log urinary β2-MG, eGFR, and maximum urine osmolality. Multivariate analysis revealed that cortical fibrosis levels (odds ratio [OR]: 1.063) and medullary stiffness (OR: 1.089) were significantly associated with medullar fibrosis (≧45%). The severe fibrosis group with both medullary fibrosis (≧45%) and cortical fibrosis (≧25%) had lower eGFR and maximum urine osmolality values and higher urinary β2-MG levels than the other groups. Conclusions Patients with disorders involving both renal medullary and cortical fibrosis had decreased maximum urine osmolality but had no abnormalities in the urinary concentrating capacities with either condition. Renal medullary and cortical fibrosis were positively correlated with urinary β2-MG, but not with urinary N-acetyl-beta-D-glucosaminidase.


  • Open Access

    Acute Kidney Injury Due to Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease Treated With Tolvaptan: A Case Report

    by Hisato Shima, Masaaki Nishitani, Hirofumi Izaki, Jun Minakuchi

    A 61-year-old asymptomatic female with autosomal dominant polycystic kidney disease (ADPKD) on tolvaptan therapy was hospitalized for acute kidney injury (AKI). Nephrolithiasis had already been diagnosed; however, the patient had not undergone any interventions. She also presented with hyponatremia possibly caused by overhydration. Because the estimated glomerular filtration rate (eGFR) decline was significantly higher than the predicted rate, we considered a possible case of postrenal AKI and examined computed tomography (CT), which revealed left hydronephrosis with a 9.4-mm ureteric stone at the level of L3/L4. We restricted fluid intake, which resulted in an increase in sodium levels. She was treated with transurethral lithotripsy (TUL) twice, which successfully improved her kidney function. Although the serum sodium levels increase because of aquaresis in almost all patients treated with tolvaptan, our case was unique in that the patient presented with hyponatremia. We should pay more attention to the periodical follow-up of nephrolithiasis in addition to the increase in total kidney volume and decide the appropriate time to treat nephrolithiasis depending on the case. We should also keep in mind that ADPKD patients have a high frequency of nephrolithiasis and, even if asymptomatic, investigate urinary tract obstruction and hydronephrosis in case of AKI.


  • Open Access

    Clinical Efficacy and Safety of Low-Dose Pemafibrate in Patients With Severe Renal Impairment: A Retrospective Study

    by Hisato Shima, Manabu Tashiro, Tomoko Inoue, Kazuyoshi Okada, Takuya Okamoto, Seiichiro Wariishi, Toshio Doi, Jun Minakuchi

    Background: The management of hypertriglyceridemia in patients with chronic kidney disease (CKD) is important. Pemafibrate, a novel selective peroxisome proliferator-activated receptor -alpha modulator with less toxic effects on liver and kidney function than those of other fibrates, has recently been approved for the treatment of patients with an estimated glomerular filtration rate (eGFR) lower than 30 mL/min/1.73 m 2 . However, the efficacy and safety of pemafibrate in patients with severe renal impairment have not yet been established. Methods: This single -center, retrospective observational study included 12 outpatients with CKD and hypertriglyceridemia, who were newly started on low -dose pemafibrate (0.1 mg/day) treatment between December 2021 and May 2023 and whose eGFRs were less than 30 mL/min/1.73 m 2 at baseline. Blood samples were collected before and at 12 weeks after pemafibrate treatment. Results: After 12 weeks of treatment, the serum triglyceride level was significantly decreased, whereas the high -density lipoprotein cholesterol level was significantly increased. The serum alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, and uric acid levels were also significantly decreased, without worsening of the eGFR and serum creatinine levels. In the subgroup analysis, there were no significant differences in the changes in clinical parameters regardless of statin use and CKD stage at baseline. Conclusions: Low -dose pemafibrate administration in patients with severe renal impairment resulted in significant improvements in triglyceride, high -density lipoprotein cholesterol, and serum uric acid levels, and liver function, without adverse events.


  • Open Access

    Impact of Albumin Leakage on the Mortality of Patients Receiving Hemodialysis or Online Hemodiafiltration

    by Manabu Tashiro, Kazuyoshi Okada, Yusaku Tanaka, Hiroyuki Michiwaki, Hisato Shima, Tomoko Inoue, Toshio Doi, Jun Minakuchi

    Background: Online hemodiafiltration (OHDF) has a lower mortality rate than hemodialysis (HD). We aimed to investigate the impact of the albumin leakage on the mortality of patients receiving HD or OHDF. Methods: In this single-center study, consecutive patients receiving renal replacement therapy between January and April 2018 were retrospectively registered. Using (1:1) propensity score matching, 3-year all-cause mortality was compared between patients receiving HD and OHDF, and the impact of albumin leakage on the mortality rate in both groups was investigated. Results: Of the 460 patients, 137 patients receiving HD were matched with an equal number of patients receiving OHDF. OHDF was associated with higher albumin leakage (p < 0.001) and a lower mortality than HD (log-rank test, p < 0.001). Albumin leakage was associated with mortality in patients receiving HD (per 1 g increase, hazard ratio (HR): 0.495, 95% confidence interval (CI): 0.275–0.888) and patients receiving OHDF (per 1 g increase, HR: 0.734, 95% CI: 0.588–0.915). Patients receiving HD, with the highest albumin leakage tertile (>3 g), had a similar mortality rate to patients receiving OHDF, with similar albumin leakage. Conclusions: The negative relationship between albumin leakage and mortality suggests the benefit of removing middle- to -large-molecular-weight substances to improve survival.


  • Open Access

    Low-density Lipoprotein Receptor Activities, Lipids, Apolipoprotein, and Clinical Course of Patients with Steroid-resistant Nephrotic Syndrome Treated with Low-density Lipoprotein Apheresis: A Case Series

    by Hisato Shima, Yusuke Higashiguchi, Toshio Doi, Megumi Harada, Takuya Okamoto, Tomoko Inoue, Manabu Tashiro, Kazuyoshi Okada, Jun Minakuchi

    We herein report three cases of steroid-resistant nephrotic syndrome successfully treated with low-density lipoprotein apheresis (LDL-A). All patients were treated with a combination of steroids, cyclosporine, and LDL-A. In all cases, the serum concentrations of LDL, total and high-density lipoprotein cholesterol, and triglycerides were significantly lowered following LDL-A administration. Furthermore, the estimated LDL receptor activity increased, while both serum LDL and total cholesterol levels decreased, suggesting that LDL-A increases LDL receptor activity by driving changes in serum cholesterol concentration. This case series suggests that LDL-A increases LDL receptor activity, which may improve the intracellular uptake of cyclosporine.


  • Open Access

    The First-Known Case of Hereditary Heterozygous Butyrylcholinesterase Deficiency in a Patient on Dialysis

    by Naoki Tokunaga, Hisato Shima, Takuya Okamoto, Masato Maekawa, Jun Minakuchi

    Serum levels of butyrylcholinesterase (BChE) are commonly used to assess liver function. Its levels have been reported to be significantly lower in patients undergoing dialysis. To the best of our knowledge, this is the first report of hereditary heterozygous BChE deficiency in a patient undergoing dialysis. Medical staff involved in the care of patients with BChE deficiency should be aware of anesthetic usage, because prolonged neuromuscular paralysis following the administration of succinylcholine or mivacurium may occur. However, in the heterozygotes, BChE activity is not completely absent. Therefore, differentiating patients undergoing dialysis is challenging. A 52-year-old man underwent living-related kidney transplantation for focal segmental glomerulosclerosis at 22 years of age. As the renal function gradually worsened, the patient began to receive combined hemodialysis and peritoneal dialysis therapy. No problems with anesthesia were observed in past surgeries. The patient’s BChE levels fluctuated between 76 and 170 U/L (reference range: 198-495 U/L); however, they had never been previously investigated. We suspected hereditary heterozygous BChE deficiency because the patient’s sister was also diagnosed with it. DNA sequencing revealed a heterozygous missense mutation (Gly365Arg) and a K-variant (Ala539Thr). Patients on dialysis with low serum BChE levels often present with low albumin levels which may be overlooked as malnutrition. Thus, BChE deficiency should be suspected in patients on dialysis with unexplained low serum BChE levels. In the case of heterozygous BChE deficiency, the reference value is low, and continuous monitoring is crucial.

  • Open Access

    Hemodialysis patients with allergic reactions to dialysate whose symptoms improved without dialysate change:Two case reports

    by Hisato Shima, Yoko Nishiuchi, Yoshio Fukata, Takuya Okamoto, Manabu Tashiro, Tomoko Inoue, Hiroyasu Bando, Hiroyuki Azuma, Naohito Iwasaka, Takuji Ohara, et al.

    血液透析患者において,透析機器関連アレルギーの診断と治療は重要である.われわれは掻痒の精査で,透析液に対する薬剤誘発性リンパ球刺激試験(DLST)陽性となり,透析液の変更を行わずに対処し,症状が改善した2例を経験した.症例1は68歳男性.カーボスターⓇPのA液のDLSTが陽性となり,プライミングを生理食塩水に変更後,症状は改善した.症例2は85歳男性.カーボスターⓇPのB液とリンパックTA3 ⓇのDLSTが陽性となり,同様の対処と膜面積を小さい透析膜に変更後,症状は消失した.これら2症例を含む,当グループにおける透析液のDLST陽性5例の特徴を検討した.掻痒以外では3例で発熱を認め,透析液変更により1例は改善したが,腫瘍熱合併のため1例は改善しなかった.1例は偽陽性と考えられた.CRPの陽性率は高かったが,好酸球数増多は1例のみであった.透析液アレルギーを疑った際,DLSTを検討するべきである.